Full-Time

Director Clinical Management

Early Phase

Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharma maker of Abilify

Compensation Overview

$186.5k - $278.9k/yr

+ Incentive opportunity

Remote in USA

Remote

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
Microsoft Outlook

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Requirements
  • Comprehensive knowledge of clinical operations, the drug development process, standard operating procedures, and Good Clinical Practice and International Council for Harmonisation regulations.
  • Thorough knowledge of contract research organizations, outsourcing, and evaluation of vendor work against Statements of Work.
  • Advanced understanding of drug development principles and clinical trial implementation and management.
  • Strong knowledge of global regulatory requirements and compliance, biostatistics, data management, and medical writing.
  • Strong communication, organization, planning, analytical, problem-solving, and people-management skills.
  • Strong computer skills and demonstrated experience using Microsoft Word, Excel, PowerPoint, and Outlook.
  • Good understanding of clinical-trial software such as electronic case report forms, interactive response technology, and clinical trial management systems.
  • Ability to travel up to 25%.
  • A Bachelor's Degree and a minimum of 14 years of applicable pharmaceutical industry experience, including 10 years of clinical trial management experience.
  • Previous supervisory experience.
Responsibilities
  • Develop and oversee the operational strategy and management of clinical programs, including coordination with internal departments and external service providers.
  • Plan, execute, and complete clinical programs according to applicable regulations, International Council for Harmonisation guidelines, Good Clinical Practices, standard operating procedures, timelines, and budgets.
  • Provide scientific clinical research and operational expertise for the strategy and objectives of the Global Clinical Development Plan, including performing or overseeing background research.
  • Represent Clinical Management in developing Clinical Development Plans, timelines, and budgets for business-development opportunities.
  • Ensure program-specific standards, including clinical trial forms, outsourcing specifications, slides, training, and templates, are developed and applied consistently across studies.
  • Contribute to final analysis and interpretation, clinical trial reports, publications, and internal and external presentations.
  • Develop program-level financial estimates and contribute to the multi-year long-term plan.
  • Lead program-level teams as co-chair and serve as the lead clinical-management representative for relevant meetings.
  • Contribute to the preparation and defense of clinical program documents, including investigator brochures, Investigational Medicinal Product Dossiers, annual regulatory reports, health-authority briefing books, and submissions, while supporting ongoing filing maintenance and labeling teams.
  • Lead development of clinical sections of regulatory documents and inspection-readiness programs where appropriate.
  • Develop scientific partnerships with key advisors in the assigned therapy area and lead program-related advisory boards, committees, and meetings.
  • Support the design and implementation of a program-level health economics and outcomes research strategy, including endpoint development where necessary.
  • Serve as the contact for Medical Affairs and related functions regarding medical-information requests, public disclosure of information, and publication strategies.
  • Represent assigned programs to senior management and disseminate information and tasks to team members.
  • Participate in external service-provider partnership governance and alliance-management activities.
  • Assist the Senior Director with portfolio-level resource planning.
  • Provide direction, training, and support to Clinical Management personnel within the program or compound team.
  • Participate in ongoing review of clinical-trial data, focusing on data integrity, trending, and consistency.
  • Ensure inspection-readiness activities are planned and conducted appropriately across the program.
  • Participate in program-level risk-mitigation activities.
  • Represent Clinical Management in departmental and cross-functional initiatives.
  • Lead or contribute to departmental, external-service-provider, and corporate standardization and continuous-improvement efforts.
  • Coordinate training and onboarding of new employees on corporate culture, goals, departmental policies, and processes when supervisory responsibilities apply.
  • Ensure assigned staff comply with departmental, standard operating procedure, compliance, and corporate training requirements.
  • Ensure assigned staff have access to required materials, systems, and training.
  • Set clear performance expectations and individual development plans and provide specific, frequent performance feedback.
  • Perform other assigned duties.
Desired Qualifications
  • An advanced degree.
Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Otsuka closed Transcend in June 2026, expanding psychiatry beyond Abilify dependence.
  • DAWNZERA gained EU authorization in January 2026, opening paid sales across 27 countries.
  • Paradise uRDN and CART BP pro broaden Japan's hypertension platform and device distribution.

What critics are saying

  • SIMTRIYO waits on DEA scheduling, delaying revenue until late 2026.
  • VOYXACT's accelerated approval depends on confirmatory kidney-outcome data; failure risks withdrawal.
  • Transcend's TSND-201 PTSD program remains clinical-stage, risking a $1.225 billion write-down.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs CNS, nephrology, and device assets across Japan, US, and Europe.
  • SIMTRIYO gives Otsuka a first-in-class ADHD stimulant franchise after July 2026 FDA approval.
  • DAWNZERA and VOYXACT anchor rare-disease pipelines with global reimbursement and accelerated paths.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.